

<b>DATE:</b>	30 January 2026
<b>TO:</b>	All Zones: Physicians, Nurses and Healthcare Providers, Laboratory Staff
<b>FROM:</b>	Clinical Biochemistry, Alberta Precision Laboratories (APL)
<b>RE:</b>	<b>Reporting Changes for Thyroglobulin and Anti-Thyroglobulin</b>

---

## PLEASE POST OR DISTRIBUTE AS WIDELY AS APPROPRIATE

---

### Key Message

- Effective immediately, the following reporting changes have been made for the Thyroglobulin and Anti-Thyroglobulin Panel at the two provincial sites performing these tests:
  1. Samples sent to the Calgary Diagnostic and Scientific Centre, DSC (Calgary Hub Lab)
    - Removal of the Thyroglobulin reference interval and replacement with an interpretative comment.
  2. Samples sent to the Calgary DSC (Calgary Hub Lab) and the University of Alberta Hospital (UAH)
    - Addition of new standardized interpretative comments appended to Thyroglobulin and Anti-Thyroglobulin results.

### Background

- The Thyroglobulin Panel reports Thyroglobulin and Anti-Thyroglobulin together.
- Accurate interpretation of Thyroglobulin requires knowledge of Anti-Thyroglobulin status.
- Removal of the Thyroglobulin reference interval at the Calgary DSC (Calgary Hub Lab) aligns with current practice at UAH.
- Thyroglobulin reference intervals have limited value because Thyroglobulin is highly variable, affected by antibodies, and not used for diagnosis of thyroid disease. Its clinical utility is for trend monitoring after thyroid cancer treatment.
- New standardized comments for Thyroglobulin and Anti-Thyroglobulin will improve interpretation of results.
- The Anti-Thyroglobulin reference interval remains unchanged.

### Action Required

- Be aware that Thyroglobulin results reported at the Calgary DSC (Calgary Hub Lab) will no longer include a reference interval and will be replaced with an interpreted comment appended to the report.
- Be aware of new standardized interpretive comments for both Thyroglobulin and Anti-Thyroglobulin appended to Calgary DSC (Calgary Hub Lab) and UAH reports.
- Refer to the [Test Directory](#) for more information.
- Test ordering procedures remain the same.

### Questions/Concerns

- Dr. Jessica Gifford, Clinical Biochemist, DSC, Calgary, 403-770-3779, [jessica.gifford@aplabs.ca](mailto:jessica.gifford@aplabs.ca)
- Dr. Josh Raizman, Clinical Biochemist, UAH, Edmonton 780-407-8492, [josh.raizman@aplabs.ca](mailto:josh.raizman@aplabs.ca)

### Approved by

- Dr. Carolyn O'Hara, Chief Medical Laboratory Officer, APL